Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00019318 · ClinicalTrials.gov registry record · Phase 1

Depsipeptide in Treating Patients With Solid Tumors

A Phase 1 study of Lymphoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00019318: Completed Phase 1 study of Lymphoma, sponsored by National Cancer Institute (NCI).

NCT00019318 is a Phase 1 study of Lymphoma that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00019318, a Phase 1 study of Lymphoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of depsipeptide in treating patients who have solid tumors for which no standard therapy exists.

Conditions Studied

Interventions

  • DRUG romidepsin

Study Locations (1)

Maryland

  • Medicine Branch - Bethesda

Trial Details

FieldValue
Start Date 1997-08
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00019318 record still lists

NCT00019318 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which romidepsin is the first listed.

NCT00019318 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00019318 about?

NCT00019318 is a clinical study titled "Depsipeptide in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of depsipeptide in treating patients who have solid tumors for which no standard therapy exists.

What is the current status of trial NCT00019318?

This trial is currently completed. It is a Phase 1 study. The study started on 1997-08.

What conditions does trial NCT00019318 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00019318?

The interventions under investigation include: romidepsin (DRUG).

Who is sponsoring clinical trial NCT00019318?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00019318 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00019318, the US trial registry maintained by the National Library of Medicine. NCT00019318 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.